Robert Reznick recently joined Orrick’s Washington, D.C., office as a partner in the Antitrust and Competition Group and the Life Sciences Industry Group.
“We are excited about Rob’s arrival,” said New York partner and managing director of litigation Jim Stengel. “Over the last several years we have grown our antitrust and competition and life sciences global platforms with significant expertise. We have a track record of seeking innovative, cooperative and collegial methods of serving the needs of our global clients.
Rob’s prominent litigation and counseling expertise is a great complement to our antitrust and competition and life sciences practices, both domestically and globally.”
Rob’s practice focuses on the counseling of pharmaceutical and other life sciences companies in connection with pricing, marketing and M&A activities, and the representation of those entities in multiplaintiff and class action litigation involving claims of price-fixing and other collusive conduct, fraud, RICO and IP-based antitrust claims. He is co-author of a chapter on the arbitration of pharmaceutical industry antitrust claims in International Arbitration: A Practical Handbook (Gordon Blanke and Phillip Landolt, Eds., Kluwer/Aspen), to be published in the spring of 2010. Formerly a partner with Hughes Hubbard & Reed LLP, Rob was co-chair of its Pharmaceutical and Healthcare Industry and Product Safety Practice Groups.
Rob also represents drug industry clients in enforcement actions against the sale of counterfeit and illegally imported and diverted drugs and medical devices, and in connection with Federal Trade Commission investigations and enforcement actions. In addition, he serves as outside counsel to the Pharmaceutical Security Institute, Inc., the brand name pharmaceutical industry’s anti-counterfeiting trade group.Rob also has extensive experience representing clients in product safety matters before the U.S. Consumer Product Safety Commission.
“Orrick’s premier global antitrust and life sciences industry-focused groups offer the highest quality of service in the global markets of most importance to clients,” said Rob. “Working with the lawyers in these groups and having the chance to integrate my practice with theirs has been enormously satisfying. The combined Orrick life sciences antitrust team provides premier service to clients in the key markets in Asia, Europe and the United States and deepens Orrick’s commitment to the provision of wide-ranging and sophisticated legal services worldwide.”